TG4050 TG4050 is an individualized therapeutic vaccine A particularly innovative immunotherapy, TG4050 is the lead myvac ® candidate. Bespoke therapeutic vaccine Phase I Ovarian cancer; HPV-negative head & neck cancers myvac® platform A particularly innovative immunotherapy, TG4050 is the lead myvac® candidate. This individualized treatment is based on the specific mutations that are identified in… Continue reading produits : TG4050
Year: 2021
produits : TG4050
produits : TG4001 teaser
TG4001 Target HPV-induced cancers (HPV-16, E6 & E7 + IL-2) TG4001, an innovative therapy capable of combating papillomavirus-induced cancers. The concept behind TG4001 is to teach the immune system to recognise and destroy the cancer cells expressing HPV-16 antigens, specifically E6 and E7 antigens. We have selected typical papillomavirus sequences that code for these antigens… Continue reading produits : TG4001 teaser
produits : TG4050 teaser
TG4050 One patient, one cancer, one vaccine With TG4050, Transgene is developing an individualized immunotherapy based on multiple advanced genetic engineering technologies and cutting-edge artificial intelligence capabilities, together with NEC. Each treatment is based on an optimized viral vector, that is customized and manufactured for each patient. It integrates the most relevant tumor targets (patient-specific… Continue reading produits : TG4050 teaser
pipeline
Product Indication Collaboration Discovery Phase I Phase II INDIVIDUALIZED NEOANTIGEN CANCER VACCINES TG4050 Head and neck cancers (adjuvant) Other indication SHARED ANTIGENS CANCER VACCINES TG4001 Anogenital HPV+ cancers Internal Shared driver mutations ONCOLYTIC VIRUSES (OV) TG6050 Lung cancer (IV*) BT-001 Solid tumors (IT*) Internal Synthetic OV… Continue reading pipeline
techno Oncolytic viruses
Oncolytic viruses With its oncolytic viruses, Transgene attacks tumors on several fronts. Oncolytics selectively multiply in cancer cells (a process called cell lysis) and indirectly trigger the activation of the immune system against the tumor. Mechanism of action of oncolytic viruses Transgene believes that oncolytic viruses, by integrating complimentary mechanisms ofaction, can become an… Continue reading techno Oncolytic viruses
techno Therapeutic Vaccines
Therapeutic Vaccines Therapeutic vaccines are active and targeted immunotherapeutics. They induce a cascade of immune reactions that lead to the production of T cells that will only destroy the targeted malignant cells. Mechanism of action of therapeutic vaccines Clinical trials evaluating our products are ongoing. Their safety profile and first efficacy data make them… Continue reading techno Therapeutic Vaccines
techno invirio
Multifunctional oncolytic viruses: a new generation of products Our proprietary oncolytic virus (OV) platform Invir.IO® allows us to design a new generation of immunotherapy. These innovative multifunctional OVs are able to modulate the tumor micro-environment to better attack cancer. Discover the concept of Invir.IO® Our patented technology can generate oncolytic viruses armed with anticancer weapons… Continue reading techno invirio
techno myvac
Individualized immunotherapy: One patient, one cancer, one vaccine With myvac®, Transgene enters the field of individualized immunotherapies with a unique virus-based immunotherapy platform. myvac® video Our approach is based on the Modified Vaccinia Ankara (MVA) viral vector, which has already been validated in clinical trials. myvac® is designed to stimulate and educate the patient’s immune… Continue reading techno myvac
conseil
Board of Directors Chairman and CEO Honorary Chairman Director Director Director, Chairman of the Strategy Committee Independent Director, Chairman of the Clinical Development Committee Director Independent Director, Chairwoman of the Audit Committee Independent Director, Chairwoman of the Compensation committee Independent Director Director, represented by Sandrine FLORY (Chairwoman of the ESG committee) Last update : June… Continue reading conseil
